FDA grants fast track designation to CMG901 for gastrointestinal cancers
The FDA granted fast track designation to CMG901 for treatment of certain patients with gastrointestinal cancers.The designation applies to use of the agent by patients with unresectable or metastatic gastric or gastroesophageal junction cancers who relapsed after or are refractory to approved therapies.CMG901 (Keymed Biosciences) is an antibody-drug conjugate that consists of three components: a monoclonal antibody that targets Claudin 18.2, a cleavable linker and a potent cytotoxic payload. Claudin 18.2 is a highly selective molecule widely expressed in solid tumors, including gastricRead More